Clinical laboratory testing is one of the most important sectors of medical
care. Although it is generally involved in over 70% of medical diagnoses, it
accounts for less than 5% of overall healthcare expenditures. The term
clinical laboratory testing usually refers to determining the concentration or
activity of a protein, carbohydrate, lipid, electrolyte, enzyme or small
molecule in easily collected body fluids such as blood, serum, plasma, urine
and saliva. This TriMark Publications report describes the specific segments
of the clinical laboratory testing business and the strategies used by
laboratory companies to develop new business opportunities. The study presents
emerging business practices and analyzes the partnerships and alliances that
various key sector players have forged or could forge in the near future. New
clinical laboratory business methods are also examined to identify lead
positions and potential future growth areas. Moreover, the report profiles
leading companies in the clinical laboratory industry, with a primary focus on
companies that actively analyze and market laboratory data.
Methodology
The author of this report is a Ph.D. in biochemistry from the University of
Minnesota with mans decades of experience in scientific writing and as a
medical industry analyst. He has been a senior director of se cml large
regional and national healthcare laboratories. He has over 30 years of
experience in laboratory testing and instrument and reagent development
technology as a licensed clinical laboraton director, as well as extensive
experience in senior level management positions in biotech and niedictil sen
ice companies. The editor has a Ph.D. in medicinal chemistry from Medical
College of Virginia, Virginia Commonwealth University, with postdoctoral work
in clinical assay development and validation conibined with molecular biology,
and has worked in small and large pharmaceutical companies in the department
of drug safet e aluation to support eflbrts in drug discovery and for
commercialization of new chemical entities as drugs for over 15 sears.
Company-specific information is obtained mainly from industry trade
publications, academic journals, news and research articles, press releases
and corporate websites, as well as annual reports for publicly-held firms.
Additionally, sources of infoimation include the non-governmental
organi/ations (NGOs) such as the World Health Organization (WHO) and
governmental entities like the U.S. Department of Hlealth and Human Services
(HHS) and U.S. federal agencies such as the National Institutes of Health
(NIH), the Food and Drug Administration (FDA) and the Centers for Disease
Control and Prevention(CDC). Where possible and practicable, the most recent
data available have been used.
Some of the statistical information was taken from Biotechnology Associates'
databases and from TriMark's private data stores. The information in this
study was obtained from sources that we believe to be reliable, but we do not
guarantee the accuracy or completeness of any information or omission or for
the results obtained by the use of such infonnation. Key information from the
business literature was used as a basis to conduct dialogue with and obtain
expert opinion from market professionals regarding commercial potential and
market sizes.
Primary Sourcesc
TriMark collects information from hundreds of Database Tables and many
comprehensive multi-client research projects, as well as Sector Snapshots that
we publish annually. We extract relevant data and analytics from TriMark' s
research as part of this data collection.
Secondary Sources
TriMark uses research publications, journals, magazines, newspapers,
newsletters, industry reports, investment research reports, trade and industry
association reports, government-affiliated trade releases and other published
information as part of its secondary research materials. The information is
then analyzed and translated by the Industry Research Group into a TriMark
study. The Editorial Group reviews the complete package with product and
market forecasts, critical industry trends, threats and opportunities,
competitive strategies and market share determinations.
Table 7.1: Myriad Genetics' Laboratory Testing Menu
Table 8.1: Key Elements of Clinical Lab Service
Table 8.2: Key Competitive Activities for Clinical Lab Service
Table 8.3: Challenges to the Clinical Lab Testing Industry
Table 8.4: Medicare Billing Guidelines for Multi-channel Clinical
Laboratory Tests
Table 8.5: Factors for Estimating Collectibility for Clinical Lab Services
Table 8.6: Classes of Lab Service Payers
Table 8.7: U.S. Revenue Forecasts for POCT Market, 2008-2018
Table 8.8: Billing Difficulties Required of Clinical Labs to Bill
Third-Party Payers
Table 8.9: Drivers for Operation of In-Office Pathology Labs
Table 8.10: Barriers for Operation of In-Office Pathology Labs
Clinical Laboratory Testing Volume 2: Key Players for Laboratory Testing, Business Trends and Strategies published by Trimark Publications in July 1, 2012. This report consists of 134 Pages and the price starts from US $ 3400.
